Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail - PubMed (original) (raw)
Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail
Donald J Wyma et al. J Virol. 2004 Apr.
Abstract
Retrovirus particles are not infectious until they undergo proteolytic maturation to form a functional core. Here we report a link between human immunodeficiency virus type 1 (HIV-1) core maturation and the ability of the virus to fuse with target cells. Using a recently developed reporter assay of HIV-1 virus-cell fusion, we show that immature HIV-1 particles are 5- to 10-fold less active for fusion with target cells than are mature virions. The fusion of mature and immature virions was rendered equivalent by truncating the gp41 cytoplasmic domain or by pseudotyping viruses with the glycoprotein of vesicular stomatitis virus. An analysis of a panel of mutants containing mutated cleavage sites indicated that HIV-1 fusion competence is activated by the cleavage of Gag at any site between the MA and NC segments and not as an indirect consequence of an altered core structure. These results suggest a mechanism by which binding of the gp41 cytoplasmic tail to Gag within immature HIV-1 particles inhibits Env conformational changes on the surface of the virion that are required for membrane fusion. This "inside-out" regulation of HIV-1 fusion could play an important role in the virus life cycle by preventing the entry of immature, noninfectious particles.
Figures
FIG. 1.
gp41 CT inhibits the fusion of immature HIV-1 particles with target cells. (a) Wild-type (NL4-3) and immature (MA/p6) HIV-1 reporter particles and corresponding mutants lacking the gp41 CT (ΔCT) were assayed for fusion with SupT1 target cells in the BlaM-Vpr reporter assay. Data shown are the mean values of duplicate determinations as a function of the quantity of virus added to the cells. The results are representative of at least three independent experiments. (b) Immunoblot analysis of viral lysates. Pelleted virions were lysed and subjected to SDS-polyacrylamide gel electrophoresis. After being transferred to nitrocellulose membranes, blots were probed sequentially with antisera that were specific for gp120, gp41, BlaM, and CA. (c) Restored fusion ability of immature HIV-1 particles lacking the gp41 CT is not due to enhanced levels of Env proteins on the virions. HIV-1 particles containing reduced levels of gp41 with the CT deleted were produced by cotransfection of the NL4-3ΔCT or MA/p6ΔCT proviral construct with various quantities of the respective Env-defective proviruses. The total quantity of proviral DNA was kept constant, at 20 μg. Values shown on the abscissa represent the amounts of Env-expressing proviral DNA used in the cotransfections. Viruses were assayed for fusion with target cells, and the fusion efficiency was expressed as a function of the fluorescence ratio per nanogram of p24 input virus. (d) Fusion activity of VSV-pseudotyped HIV-1. Reporter particles were produced by the cotransfection of a pNL4-3Env− or pNL-MA/p6Env− proviral clone with pHCMV-G (34) and the BlaM-Vpr expression construct pMM310. Threefold dilutions of the viruses were tested to verify the dose dependence of the assay for pseudotyped particles. The virus dilutions were reassayed by p24 ELISAs to confirm the accuracy of the dilutions. Results shown are the averages of duplicate determinations from one of two independent experiments.
FIG. 2.
Cleavage of Gag between MA and NC is required for efficient HIV-1 fusion. (a) Schematic of Gag cleavage site mutants. The CA6 mutant was previously described (32). PCR overlap extension was used to replace the P1 amino acid of the remaining Pr55Gag cleavage sites with an Ile, which prevents cleavage by the HIV-1 PR. (b) SupT1 cells were inoculated with wild-type (NL4-3) reporter particles or Gag cleavage mutants, and fusion was assayed as described for Fig. 1. Results shown are the averages of duplicate determinations (which typically varied by <10%) from one of two independent experiments. (c) Immunoblot analysis of Pr55Gag cleavage site mutants for gp120, gp41, BlaM, and CA.
FIG. 3.
Transmission electron microscopy of mutant HIV-1 particles. Wild-type (WT) and Gag cleavage site mutant (MA/CA, MA/p2, MA/NC, and MA/p6) proviruses were transfected into 293T cells; the cells were cultured for 1 day and then harvested, fixed, sectioned, and stained; and the samples were analyzed by electron microscopy. Scale bars are shown in micrometers. All of the transfections yielded large quantities of HIV-1 particles of similar sizes, but with distinct internal morphologies.
Similar articles
- Exploring HIV-1 Maturation: A New Frontier in Antiviral Development.
McGraw A, Hillmer G, Medehincu SM, Hikichi Y, Gagliardi S, Narayan K, Tibebe H, Marquez D, Mei Bose L, Keating A, Izumi C, Peese K, Joshi S, Krystal M, DeCicco-Skinner KL, Freed EO, Sardo L, Izumi T. McGraw A, et al. Viruses. 2024 Sep 6;16(9):1423. doi: 10.3390/v16091423. Viruses. 2024. PMID: 39339899 Free PMC article. Review. - Maturation-dependent human immunodeficiency virus type 1 particle fusion requires a carboxyl-terminal region of the gp41 cytoplasmic tail.
Jiang J, Aiken C. Jiang J, et al. J Virol. 2007 Sep;81(18):9999-10008. doi: 10.1128/JVI.00592-07. Epub 2007 Jul 3. J Virol. 2007. PMID: 17609279 Free PMC article. - Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions.
Freed EO, Martin MA. Freed EO, et al. J Virol. 1996 Jan;70(1):341-51. doi: 10.1128/JVI.70.1.341-351.1996. J Virol. 1996. PMID: 8523546 Free PMC article. - A mutation in the human immunodeficiency virus type 1 Gag protein destabilizes the interaction of the envelope protein subunits gp120 and gp41.
Davis MR, Jiang J, Zhou J, Freed EO, Aiken C. Davis MR, et al. J Virol. 2006 Mar;80(5):2405-17. doi: 10.1128/JVI.80.5.2405-2417.2006. J Virol. 2006. PMID: 16474147 Free PMC article. - The Interplay between HIV-1 Gag Binding to the Plasma Membrane and Env Incorporation.
Murphy RE, Saad JS. Murphy RE, et al. Viruses. 2020 May 16;12(5):548. doi: 10.3390/v12050548. Viruses. 2020. PMID: 32429351 Free PMC article. Review.
Cited by
- Exploring HIV-1 Maturation: A New Frontier in Antiviral Development.
McGraw A, Hillmer G, Medehincu SM, Hikichi Y, Gagliardi S, Narayan K, Tibebe H, Marquez D, Mei Bose L, Keating A, Izumi C, Peese K, Joshi S, Krystal M, DeCicco-Skinner KL, Freed EO, Sardo L, Izumi T. McGraw A, et al. Viruses. 2024 Sep 6;16(9):1423. doi: 10.3390/v16091423. Viruses. 2024. PMID: 39339899 Free PMC article. Review. - Insect cell production of chimeric virus-like particles based on human immunodeficiency virus GAG proteins and yellow fever virus envelope protein.
da Silva Morgado F, Cahú R, de Jesus DC, de Souza Chaves LC, Ribeiro BM. da Silva Morgado F, et al. Braz J Microbiol. 2024 Sep 10. doi: 10.1007/s42770-024-01509-5. Online ahead of print. Braz J Microbiol. 2024. PMID: 39254800 - The evolution of envelope function during coinfection with phylogenetically distinct human immunodeficiency virus.
Omar S, Woodman ZL. Omar S, et al. BMC Infect Dis. 2024 Sep 9;24(1):934. doi: 10.1186/s12879-024-09805-z. BMC Infect Dis. 2024. PMID: 39251948 Free PMC article. - The HIV-1 capsid serves as a nanoscale reaction vessel for reverse transcription.
Jennings J, Bracey H, Hong J, Nguyen DT, Dasgupta R, Rivera AV, Sluis-Cremer N, Shi J, Aiken C. Jennings J, et al. PLoS Pathog. 2024 Sep 3;20(9):e1011810. doi: 10.1371/journal.ppat.1011810. eCollection 2024 Sep. PLoS Pathog. 2024. PMID: 39226318 Free PMC article. - Second site reversion of HIV-1 envelope protein baseplate mutations maps to the matrix protein.
Alfadhli A, Romanaggi C, Barklis RL, Barklis E. Alfadhli A, et al. J Virol. 2024 Feb 20;98(2):e0174223. doi: 10.1128/jvi.01742-23. Epub 2024 Jan 9. J Virol. 2024. PMID: 38193694 Free PMC article.
References
- Cavrois, M., C. De Noronha, and W. C. Greene. 2002. A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat. Biotechnol. 20:1151-1154. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources